Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Presented By Halle Moore at 2014 ASCO Annual Meeting
Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without.
Highlights of the Day:Central Nervous System Tumors
Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting
Presented By John Byrd at 2014 ASCO Annual Meeting
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Presented By Xabier Garcia-Albeniz at 2014 ASCO Annual Meeting
Presented By Joyce Liu at 2014 ASCO Annual Meeting
